LINPS: a database for cancer-cell-specific perturbations of biological networks

Mahmoud Ahmed1, Deok Ryong Kim1

  • 1Department of Biochemistry and Convergence Medical Science, Institute of Health Sciences, Gyeongsang National University College of Medicine, 816 Beon-gil 15, Jinju-daero, Jinju 52727, South Korea.

Insights

This study developed a database to help scientists screen cancer therapies by analyzing drug effects on biological networks. The tool makes complex data accessible, aiding cancer research and drug discovery.

Area of Science:

  • Computational Biology
  • Bioinformatics
  • Cancer Research

Background:

  • Screening cancer therapies from large drug perturbation datasets is resource-intensive and requires specialized expertise.
  • Access to valuable drug perturbation data is often limited for many lab scientists.
  • Causal biological networks (CBN) offer a structured way to leverage prior biological knowledge.

Purpose of the Study:

  • To create an accessible resource for analyzing drug perturbation effects on biological networks.
  • To simplify the process of identifying potential cancer therapies for researchers.
  • To bridge the gap between large biological datasets and practical laboratory application.

Main Methods:

  • Utilized the Library of Integrated Cellular Signatures (LINCS) to model drug effects on gene expression.
  • Applied network perturbation amplitudes analysis to predict drug impacts on CBN.
  • Developed a database with an interactive web interface to host pre-computed analysis results.

Main Results:

  • Generated cell-specific drug perturbation signatures for hundreds of treatments.
  • Quantified the effects of drug treatments on multiple key biological functions within cancer cell lines.
  • Successfully packaged pre-computed network perturbation scores into a user-friendly database.

Conclusions:

  • The developed database and interactive interface democratize access to drug perturbation analysis for cancer research.
  • Researchers can now efficiently query and interpret drug effects on biological networks.
  • This resource facilitates the discovery of novel cancer therapies by leveraging existing biological data.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.1K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K